Dianthus Therapeutics, Inc. (DNTH) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • Heavy cash burn • Deep losses DNTH has exceptionally strong liquidity and minimal debt, but its core business remains deeply unprofitable with severe cash burn and weak returns, making the current valuation hard to justify.
Price Behavior
Key Price Behavior Insights: • Support hold • Resistance ceiling • Momentum fade Support Level: $84.56 to $86.20 Resistance Level: $91.29 to $95.76 DNTH remains constructive short term as it has rebounded from 78.55 to 87.39, but it must hold the mid-$80s support and reclaim the low-$90s resistance zone to keep the recovery intact.
Sentiment & News
Key News Insights: • Price momentum • Institutional buying • CFO selling DNTH showed strong price action and renewed institutional interest, but heavy CFO share sales and mixed analyst-support signals temper the bullish read. #insider-selling
AI Summary
DNTH has shifted from a pure cash-burn biotech story to a funded, catalyst-driven bet on claseprubart, where the March “go” decision and large cash runway reduce near-term financing risk but the investment now hinges almost entirely on proving clinical efficacy and avoiding dilution-driven disappointment.
Description
Dianthus Therapeutics is a clinical‑stage biotechnology firm developing monoclonal antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, DNTH103, is in Phase 1 clinical trials for generalized myasthenia gravis and several immune‑mediated neuropathies. The company was founded in 2015 and is based in New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 9 | Mar 16 | DNTH | Dianthus Therapeutics, Inc. | Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days. | Closed | -1.6% |